Wutah pendapatan taun lumaku: Inhibrx Corp (INBX)

The GURU.Markets terminal line chart, illustrating the year-over-year sales volume growth over the last 12 months, recorded a figure of 43.10. Inhibrx Biosciences (INBX) generates revenue based on royalties and payments from Sanofi for the drug INBRX-101. The company minimizes risks by developing protein-based therapies for cancer and rare pathologies, while enhancing drug discovery efficiency through the implementation of robotic screening systems.
Inhibrx Biosciences - rincian analitis lan metrik utama (INBX)

This indicator measures operational efficiency by recalculating annual revenue growth over a rolling period, allowing for an assessment of business scaling rates and asset stagnation risks. Since Inhibrx Biosciences (INBX) focuses on early-stage antibody development and lacks commercial sales, the comparative rolling year-over-year sales dynamics merely reflect the absence of current cash flow prior to the completion of clinical trials.